Cargando…
Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study
The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs). We retrospectively enrolled 93 newly diagnosed CML...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969257/ https://www.ncbi.nlm.nih.gov/pubmed/33725811 http://dx.doi.org/10.1097/MD.0000000000024003 |
_version_ | 1783666206486560768 |
---|---|
author | Mao, Xia-Li Xi, Ya-Ming Li, Zi-Jian Jia, Ming-Feng Li, Ming Wang, Li-Na Zhao, Long Zhang, Hao |
author_facet | Mao, Xia-Li Xi, Ya-Ming Li, Zi-Jian Jia, Ming-Feng Li, Ming Wang, Li-Na Zhao, Long Zhang, Hao |
author_sort | Mao, Xia-Li |
collection | PubMed |
description | The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs). We retrospectively enrolled 93 newly diagnosed CML-CP patients treated with TKIs from 2009 to 2018 at the First Hospital of Lanzhou University. Patients were divided into 2 groups using an RDW of 18.65% determined by receiver operating characteristic curve analysis. We analyzed the correlation of treatment responses and the RDW compared to common scoring systems, as well as the correlation of the RDW with disease outcome, including overall survival (OS) and progression-free survival (PFS), and demographic and laboratory factors affecting outcome. Univariate analysis and Cox regression analysis were used. The median age of patients was 40 years, and 51 patients (54.8%) were men. A high RDW could predict treatment response at 3 months (P = .03) and 6 months (P = .02). The RDW was significantly lower in patients who achieved molecular response by 3 months (P < .001) and complete cytogenetic response by 6 months (P = .001) than in those who did not respond. Patients with a high RDW (>18.65%, n = 35) had significantly worse 5-year OS (77.1% vs 96.6%; P = .008) and PFS (80.0% vs 98.3%; P = .002) than those with a low RDW (≤18.65%, n = 58). Multivariate analysis demonstrated that a high RDW was an adverse predictor of OS (P = .005, HR (hazard ratio) = 9.741) and PFS (P = .009, HR = 16.735). The RDW is a readily available prognostic marker of outcome in patients with CML-CP and can predict treatment response to TKIs. Further larger and prospective studies are required. |
format | Online Article Text |
id | pubmed-7969257 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-79692572021-03-18 Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study Mao, Xia-Li Xi, Ya-Ming Li, Zi-Jian Jia, Ming-Feng Li, Ming Wang, Li-Na Zhao, Long Zhang, Hao Medicine (Baltimore) 4800 The aim of this study was to evaluate the ability of the red blood cell distribution width (RDW) to predict prognosis and treatment response in chronic myeloid leukemia (CML)-chronic phase (CP) patients treated with tyrosine kinase inhibitor (TKIs). We retrospectively enrolled 93 newly diagnosed CML-CP patients treated with TKIs from 2009 to 2018 at the First Hospital of Lanzhou University. Patients were divided into 2 groups using an RDW of 18.65% determined by receiver operating characteristic curve analysis. We analyzed the correlation of treatment responses and the RDW compared to common scoring systems, as well as the correlation of the RDW with disease outcome, including overall survival (OS) and progression-free survival (PFS), and demographic and laboratory factors affecting outcome. Univariate analysis and Cox regression analysis were used. The median age of patients was 40 years, and 51 patients (54.8%) were men. A high RDW could predict treatment response at 3 months (P = .03) and 6 months (P = .02). The RDW was significantly lower in patients who achieved molecular response by 3 months (P < .001) and complete cytogenetic response by 6 months (P = .001) than in those who did not respond. Patients with a high RDW (>18.65%, n = 35) had significantly worse 5-year OS (77.1% vs 96.6%; P = .008) and PFS (80.0% vs 98.3%; P = .002) than those with a low RDW (≤18.65%, n = 58). Multivariate analysis demonstrated that a high RDW was an adverse predictor of OS (P = .005, HR (hazard ratio) = 9.741) and PFS (P = .009, HR = 16.735). The RDW is a readily available prognostic marker of outcome in patients with CML-CP and can predict treatment response to TKIs. Further larger and prospective studies are required. Lippincott Williams & Wilkins 2021-03-12 /pmc/articles/PMC7969257/ /pubmed/33725811 http://dx.doi.org/10.1097/MD.0000000000024003 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 |
spellingShingle | 4800 Mao, Xia-Li Xi, Ya-Ming Li, Zi-Jian Jia, Ming-Feng Li, Ming Wang, Li-Na Zhao, Long Zhang, Hao Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title | Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title_full | Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title_fullStr | Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title_full_unstemmed | Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title_short | Higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: A retrospective study |
title_sort | higher red blood cell distribution width at diagnose is a simple negative prognostic factor in chronic phase-chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: a retrospective study |
topic | 4800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969257/ https://www.ncbi.nlm.nih.gov/pubmed/33725811 http://dx.doi.org/10.1097/MD.0000000000024003 |
work_keys_str_mv | AT maoxiali higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT xiyaming higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT lizijian higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT jiamingfeng higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT liming higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT wanglina higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT zhaolong higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy AT zhanghao higherredbloodcelldistributionwidthatdiagnoseisasimplenegativeprognosticfactorinchronicphasechronicmyeloidleukemiapatientstreatedwithtyrosinekinaseinhibitorsaretrospectivestudy |